FTII
FutureTech II Acquisition Corp.12.02
+0.00+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
51.57MP/E (TTM)
-Basic EPS (TTM)
-0.42Dividend Yield
0%Recent Filings
8-K
Advisory deal, note corrected
FutureTech II Acquisition Corp. signed an exclusive financial advisory deal with D. Boral Capital on March 4, 2026, for its pending De-SPAC merger with Longevity Biomedical, granting D. Boral a 36-month post-closing right of first refusal on all equity/debt raises and M&A. It also corrected a $1,475,000 promissory note to D. Boral, tying repayment to merger close or February 4, 2026 maturity. Deal hinges on Business Combination.
8-K
New auditor appointed
FutureTech II Acquisition Corp. appointed CBIZ CPAs P.C. as its new independent registered public accounting firm on February 17, 2026, effective for the fiscal year ended December 31, 2025. CBIZ will audit the 2025 financials and review Q3 2025 interim statements. No prior consultations or disagreements occurred. Smooth transition, no issues flagged.
8-K
Auditor resigns abruptly
FutureTech II Acquisition Corp.'s auditor, Adeptus Partners, resigned effective January 12, 2026, after serving since 2021. No disagreements on accounting or audits, but prior reports flagged going concern doubts and material weaknesses in controls and financial reporting. The SPAC now hunts a new auditor. Exhibit 16.1 confirms Adeptus concurs.
8-K
Terminates $1M notes early
10-Q
Q2 FY2025 results
FutureTech II's Q2 ended June 30, 2025 showed a net loss of $80,647, up from $44,457 y/y, with expenses of $138,735 versus $284,894 as trust interest fell to $72,477 from $283,084 amid heavy redemptions. Six-month loss hit $370,320 from $592,572 costs against $272,304 interest, versus prior profit. Trust holds $9.1M at $12.54/share for 779,886 redeemable shares; cash $161K but $5.5M working capital deficit, offset by $4.4M sponsor notes. Merger with Longevity advances, now eyeing Nasdaq relisting as LBIO. Delisting hangs over trading.
AACB
Artius II Acquisition Inc.
10.31+0.00
ATEK
Athena Technology Acquisition C
9.02+0.00
ATII
Archimedes Tech SPAC Partners I
10.37-0.01
CCII
Cohen Circle Acquisition Corp.
10.23-0.03
FVN
Future Vision II Acquisition Co
10.54+0.00
KFII
K&F Growth Acquisition Corp. II
10.31+0.00
RFAI
RF Acquisition Corp II
10.74+0.02
SVII
Spring Valley Acquisition Corp.
12.70+0.00
SZZL
Sizzle Acquisition Corp. II
10.17+0.00
YOTA
Yotta Acquisition Corporation
2.00+0.00